GGrantIndex
← Leaderboards

Bradford Alan Woodworth

University Of Alabama At Birmingham

$3,946,767
Attributed
$3,946,767
Total exposure
4
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $608.2K · FY201124
$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24

Funding mix

By agency

NIH$3,946,767 · 4

By mechanism

R01$1,735,567 · 1
P30$1,138,557 · 1
K08$667,980 · 1
R21$404,663 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Alabama At Birmingham

Same institution · by research overlap

Others in their field

Top investigators on “In Vivo

Research focus

In VivoCystic Fibrosis Transmembrane Conductance RegulatorFunctional DisorderCystic FibrosisNoseIn VitroViscosityClinical TrialsMucociliary ClearanceMucous Body SubstanceNovel TherapeuticsEpithelialMorbidity - Disease RateIon TransportLaboratoriesEpitheliumAnionsPathway InteractionsPatch ClampResponseMediatingNasal EpitheliumCellsInflammation

Grant awards (17)

A Ginsenoside TMEM16A Potentiator for Cystic Fibrosis$181,913
R21 · FY2024 · AT · contact PI
A Ginsenoside TMEM16A Potentiator for Cystic Fibrosis$222,750
R21 · FY2023 · AT · contact PI
Core A: Cell Model and Evaluation Core$241,719
P30 · FY2022 · DK · contact PI
Core A: Cell Model and Evaluation Core$241,719
P30 · FY2021 · DK · contact PI
Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis$318,014
R01 · FY2020 · HL · contact PI
Core A: Cell Model and Evaluation Core$171,681
P30 · FY2020 · DK · contact PI
Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis$318,014
R01 · FY2019 · HL · contact PI
Core A: Cell Model and Evaluation Core$241,719
P30 · FY2019 · DK · contact PI
Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis$366,513
R01 · FY2018 · HL · contact PI
Core A: Cell Model and Evaluation Core$241,719
P30 · FY2018 · DK · contact PI
Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis$366,513
R01 · FY2017 · HL · contact PI
Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis$366,513
R01 · FY2016 · HL · contact PI
Chloride secretagogues for acquired CFTR dysfunction in chronic rhinosinusitis$133,596
K08 · FY2015 · HL · contact PI
Chloride secretagogues for acquired CFTR dysfunction in chronic rhinosinusitis$133,596
K08 · FY2014 · HL · contact PI
Chloride secretagogues for acquired CFTR dysfunction in chronic rhinosinusitis$133,596
K08 · FY2013 · HL · contact PI
Chloride secretagogues for acquired CFTR dysfunction in chronic rhinosinusitis$133,596
K08 · FY2012 · HL · contact PI
Chloride secretagogues for acquired CFTR dysfunction in chronic rhinosinusitis$133,596
K08 · FY2011 · HL · contact PI